These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 36651532)

  • 21. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
    Silberstein SD; Lipton RB; Dodick DW; Freitag FG; Ramadan N; Mathew N; Brandes JL; Bigal M; Saper J; Ascher S; Jordan DM; Greenberg SJ; Hulihan J;
    Headache; 2007 Feb; 47(2):170-80. PubMed ID: 17300356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study.
    Landy S; Munjal S; Brand-Schieber E; Rapoport AM
    J Headache Pain; 2018 Aug; 19(1):70. PubMed ID: 30112725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and tolerability of short-term preventive frovatriptan: a combined analysis.
    MacGregor EA; Brandes JL; Silberstein S; Jeka S; Czapinski P; Shaw B; Pawsey S
    Headache; 2009 Oct; 49(9):1298-314. PubMed ID: 19788471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial.
    Boinpally R; Spaventa J; Chen K; Butler M
    Clin Drug Investig; 2021 Jun; 41(6):557-567. PubMed ID: 33948911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atogepant for the prevention of episodic migraine in adults.
    Switzer MP; Robinson JE; Joyner KR; Morgan KW
    SAGE Open Med; 2022; 10():20503121221128688. PubMed ID: 36226229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy and safety of atogepant for the prophylactic treatment of migraine: evidence from randomized controlled trials.
    Tao X; Yan Z; Meng J; Wang W; Dai Q; Zhou Q; Wang Z; Wang Z
    J Headache Pain; 2022 Jan; 23(1):19. PubMed ID: 35093013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults.
    Min KC; Kraft WK; Bondiskey P; Colón-González F; Liu W; Xu J; Panebianco D; Mixson L; Dockendorf MF; Matthews CZ; Boinpally R
    Clin Transl Sci; 2021 Mar; 14(2):599-605. PubMed ID: 33142014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study.
    Ashina M; Cohen JM; Galic M; Campos VR; Barash S; Ning X; Kessler Y; Janka L; Diener HC
    J Headache Pain; 2021 Jul; 22(1):68. PubMed ID: 34246226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.
    Dodick DW; Goadsby PJ; Silberstein SD; Lipton RB; Olesen J; Ashina M; Wilks K; Kudrow D; Kroll R; Kohrman B; Bargar R; Hirman J; Smith J;
    Lancet Neurol; 2014 Nov; 13(11):1100-1107. PubMed ID: 25297013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
    Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
    J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model.
    Thaliffdeen R; Yu A; Rascati K
    Clin Drug Investig; 2024 Mar; 44(3):209-217. PubMed ID: 38381352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Small molecule CGRP receptor antagonists for the preventive treatment of migraine: A review.
    Dos Santos JBR; da Silva MRR
    Eur J Pharmacol; 2022 May; 922():174902. PubMed ID: 35358493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and Safety of Coadministered Atogepant and Topiramate in Healthy Participants: A Phase 1, Open-Label, Drug-Drug Interaction Study.
    Boinpally R; McGeeney D; Borbridge L; Trugman J
    Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1013-1021. PubMed ID: 37210713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
    Ashina M; Saper J; Cady R; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Smith J
    Cephalalgia; 2020 Mar; 40(3):241-254. PubMed ID: 32075406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
    Apostol G; Pakalnis A; Laforet GA; Robieson WZ; Olson E; Abi-Saab WM; Saltarelli M
    Headache; 2009 Jan; 49(1):36-44. PubMed ID: 19040678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.